The Role of ImmuKnow® in the Management of Immunosuppressants in the Renal Transplant Patient

Stopped early · Phase 4

Conditions studied: Kidney Transplant Immunosuppression

In brief

The purpose of this study is to demonstrate whether there are any outcome benefits of a serial ImmuKnow assays in the management of de novo renal transplant recipients.

Key facts

Study ID

NCT01424345

Run by

CAMC Health System

People needed

4

Starts

2011-12-01

Expected to finish

2012-07-01

Last updated by the study team

2026-03-20

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• De novo kidney transplant patients who are eligible for kidney transplant according to UNOS criteria and agree to participate in the study.
• Patients of both sex aged between 18 to 80 years.

You may not qualify if…

• Any patient with a known immunocompromised disease (e.g. patients with AIDS) or leukocytosis(>15,000u/L)

Where it is running

• CAMC — Charleston, West Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.